SARS-CoV-2 Spike protein S1 containing both D614G and N501Y amino acid changes relative to the Wuhan-Hu-1 isolate. The N501Y mutation has been reported to increase binding affinity to human ACE2.
SARS-CoV-2 Spike protein S1 containing both D614G and N501Y amino acid changes relative to the Wuhan-Hu-1 isolate. The N501Y mutation has been reported to increase binding affinity to human ACE2.
Recombinant SARS-CoV-2 Spike Glycoprotein S1 containing the D614G mutation relative to Wuhan-Hu-1. Protein was produced in HEK293 cells and purified from culture supernatant by Protein G chromatography.
SARS-CoV-2 Spike protein receptor binding domain (RBD) produced in HEK293 cells. The protein was purified from culture supernatant by immobilised metal affinity chromatography
SARS-CoV-2 Spike protein receptor binding domain (RBD) produced in HEK293 cells. The protein was purified from culture supernatant by immobilised metal affinity chromatography
Trimeric SARS-CoV-2 spike protein, with D614G mutation, in prefusion confirmation. C-terminal transmembrane region is replaced with a trimerization domain and a polyhistidine tag. Contains two stabilizing proline mutations and scrambled S1/S2 furin cleavage site (Wrapp et al., 2020).
SARS-CoV-2 Spike protein S1 containing both D614G and N501Y amino acid changes relative to the Wuhan-Hu-1 isolate. The N501Y mutation has been reported to increase binding affinity to human ACE2.